Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer-Reference-Cited by-同舟云学术

Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer

Published:2009-12 Issue:3 Volume:93 Page:654
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Chan Andrew,Teoh Daren,Sanghera Paul,Hartley Andrew

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference4 articles.

1. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck;Bonner;N Eng J Med,2006

2. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer;Pryor;Radiother Oncol,2009

3. National Institute for Health and Clinical Excellence. Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck. Final appraisal determination; 30 April 2008.

4. Hypofractionated accelerated radiotherapy with concurrent chemotherapy for locally advanced squamous cell carcinoma of the head and neck;Sanghera;Int J Radiat Oncol Biol Phys,2007

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypofractionated chemoradiation for head and cancer: Data from the PET NECK trial;Oral Oncology;2021-02

2. Hypofractionated radiotherapy combined with cetuximab in vulnerable elderly patients with locally advanced head and neck squamous cell carcinoma;Medical Oncology;2019-06-12

3. Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review;Critical Reviews in Oncology/Hematology;2017-12

4. Impact of fraction size on locally advanced oropharyngeal and nasopharyngeal cancers treated with chemoradiation;Oral Oncology;2017-05

5. Cancer Therapies: Current Scenario, Management, and Safety Aspects;Anticancer Plants: Clinical Trials and Nanotechnology;2017